← Leaderboards
Karteek Kadimisetty
Lifesensors, Inc.
$4,213,826
Attributed
$4,213,826
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2019–24$2M$1.5M$1M$500K$0
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,213,826 · 6
By mechanism
R44$2,992,308 · 2
R43$1,221,518 · 4
Top collaborators
No co-investigators on record.
Most similar at Lifesensors, Inc.
Same institution · by research overlap
- Tauseef R. Butt$12,263,110
- Bryant Darnay$300,000
Others in their field
Other Emerging Leaders on “Binding”
- Xinhua Li · Nano Terra, Inc.$35,520,438
- John Damon Chodera · Sloan-Kettering Inst Can Research$21,305,909
- Tharick Pascoal · University Of Pittsburgh At Pittsburgh$20,465,582
- Suzanne L Baker · University Of Pittsburgh At Pittsburgh$20,465,582
- Kristian Graugaard Andersen · Scripps Research Institute, The$18,732,618
- Steven Armen Boyd · Venatorx Pharmaceuticals, Inc.$13,685,544
Research focus
BindingMonitorUbiquitinCellsPlayDesignProteinsMulticatalytic Endopeptidase ComplexMediatingUbiquitin-Protein LigaseProtein TransportUbiquitinationSmall MoleculePharmaceutical PreparationsDrug DiscoverySpecificityProtacProtein DegradationMorphologic ArtifactsAutophagocytosisLigaseFamilyChimera DrugNeurons
Grant awards (7)
Molecular glue degraders for LRRK2$299,978
R43 · FY2024 · GM · contact PI
Novel Approaches for Tau PROTAC Drug Discovery$1,254,536
R44 · FY2023 · AG · contact PI
Rational design of bifunctional protein degrader drugs$733,586
R44 · FY2022 · GM · contact PI
Rational design of bifunctional protein degrader drugs$1,004,186
R44 · FY2021 · GM · contact PI
Novel Approaches for PROTAC Drug Discovery$397,101
R43 · FY2020 · AG · contact PI
Rational design of bifunctional protein degrader drugs$299,611
R43 · FY2019 · GM · contact PI
Determining the signatures of pan-ubiquitylation in the immune proteome as highly sensitive and effective markers for neurodegenerative disease$224,828
R43 · FY2019 · AG · contact PI